Merkel cell carcinoma.
Identifieur interne : 000352 ( PubMed/Corpus ); précédent : 000351; suivant : 000353Merkel cell carcinoma.
Auteurs : Jürgen C. Becker ; Andreas Stang ; James A. Decaprio ; Lorenzo Cerroni ; Celeste Lebbé ; Michael Veness ; Paul NghiemSource :
- Nature reviews. Disease primers [ 2056-676X ] ; 2017.
Abstract
Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations. Notably, in the Northern hemisphere, the majority of MCC cases are of viral aetiology; by contrast, in areas with high UV exposure, UV-mediated carcinogenesis is predominant. The two aetiologies share similar clinical, histopathological and prognostic characteristics. MCC presents with a solitary cutaneous or subcutaneous nodule, most frequently in sun-exposed areas. In fact, UV exposure is probably involved in both viral-mediated and non-viral-mediated carcinogenesis, by contributing to immunosuppression or DNA damage, respectively. Confirmation of diagnosis relies on analyses of histological features and immunological marker expression profiles of the lesion. At primary diagnosis, loco-regional metastases are already present in ∼30% of patients. Excision of the tumour is the first-line therapy; if not feasible, radiotherapy can often effectively control the disease. Chemotherapy was the only alternative in advanced-stage or refractory MCC until several clinical trials demonstrated the efficacy of immune-checkpoint inhibitors.
DOI: 10.1038/nrdp.2017.77
PubMed: 29072302
Links to Exploration step
pubmed:29072302Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Merkel cell carcinoma.</title><author><name sortKey="Becker, Jurgen C" sort="Becker, Jurgen C" uniqKey="Becker J" first="Jürgen C" last="Becker">Jürgen C. Becker</name><affiliation><nlm:affiliation>Departments of Translational Skin Cancer Research and Dermatology, University Hospital Essen, Universitätsstrasse 1, 45141 Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Stang, Andreas" sort="Stang, Andreas" uniqKey="Stang A" first="Andreas" last="Stang">Andreas Stang</name><affiliation><nlm:affiliation>German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf and German Cancer Research Center (DKFZ), Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Decaprio, James A" sort="Decaprio, James A" uniqKey="Decaprio J" first="James A" last="Decaprio">James A. Decaprio</name><affiliation><nlm:affiliation>Merkel Cell Carcinoma Center of Excellence, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cerroni, Lorenzo" sort="Cerroni, Lorenzo" uniqKey="Cerroni L" first="Lorenzo" last="Cerroni">Lorenzo Cerroni</name><affiliation><nlm:affiliation>Department of Dermatology, Medical University of Graz, Graz, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbé">Celeste Lebbé</name><affiliation><nlm:affiliation>APHP, Department of Dermatology, Saint-Louis Hospital, Sorbonne Paris Cité Université Paris Diderot, INSERM U976, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Veness, Michael" sort="Veness, Michael" uniqKey="Veness M" first="Michael" last="Veness">Michael Veness</name><affiliation><nlm:affiliation>Department of Radiation Oncology and Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nghiem, Paul" sort="Nghiem, Paul" uniqKey="Nghiem P" first="Paul" last="Nghiem">Paul Nghiem</name><affiliation><nlm:affiliation>Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29072302</idno><idno type="pmid">29072302</idno><idno type="doi">10.1038/nrdp.2017.77</idno><idno type="wicri:Area/PubMed/Corpus">000352</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000352</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Merkel cell carcinoma.</title><author><name sortKey="Becker, Jurgen C" sort="Becker, Jurgen C" uniqKey="Becker J" first="Jürgen C" last="Becker">Jürgen C. Becker</name><affiliation><nlm:affiliation>Departments of Translational Skin Cancer Research and Dermatology, University Hospital Essen, Universitätsstrasse 1, 45141 Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Stang, Andreas" sort="Stang, Andreas" uniqKey="Stang A" first="Andreas" last="Stang">Andreas Stang</name><affiliation><nlm:affiliation>German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf and German Cancer Research Center (DKFZ), Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Decaprio, James A" sort="Decaprio, James A" uniqKey="Decaprio J" first="James A" last="Decaprio">James A. Decaprio</name><affiliation><nlm:affiliation>Merkel Cell Carcinoma Center of Excellence, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cerroni, Lorenzo" sort="Cerroni, Lorenzo" uniqKey="Cerroni L" first="Lorenzo" last="Cerroni">Lorenzo Cerroni</name><affiliation><nlm:affiliation>Department of Dermatology, Medical University of Graz, Graz, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbé">Celeste Lebbé</name><affiliation><nlm:affiliation>APHP, Department of Dermatology, Saint-Louis Hospital, Sorbonne Paris Cité Université Paris Diderot, INSERM U976, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Veness, Michael" sort="Veness, Michael" uniqKey="Veness M" first="Michael" last="Veness">Michael Veness</name><affiliation><nlm:affiliation>Department of Radiation Oncology and Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nghiem, Paul" sort="Nghiem, Paul" uniqKey="Nghiem P" first="Paul" last="Nghiem">Paul Nghiem</name><affiliation><nlm:affiliation>Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Nature reviews. Disease primers</title><idno type="eISSN">2056-676X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations. Notably, in the Northern hemisphere, the majority of MCC cases are of viral aetiology; by contrast, in areas with high UV exposure, UV-mediated carcinogenesis is predominant. The two aetiologies share similar clinical, histopathological and prognostic characteristics. MCC presents with a solitary cutaneous or subcutaneous nodule, most frequently in sun-exposed areas. In fact, UV exposure is probably involved in both viral-mediated and non-viral-mediated carcinogenesis, by contributing to immunosuppression or DNA damage, respectively. Confirmation of diagnosis relies on analyses of histological features and immunological marker expression profiles of the lesion. At primary diagnosis, loco-regional metastases are already present in ∼30% of patients. Excision of the tumour is the first-line therapy; if not feasible, radiotherapy can often effectively control the disease. Chemotherapy was the only alternative in advanced-stage or refractory MCC until several clinical trials demonstrated the efficacy of immune-checkpoint inhibitors.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">29072302</PMID><DateCreated><Year>2017</Year><Month>10</Month><Day>26</Day></DateCreated><DateRevised><Year>2017</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-676X</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2017</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature reviews. Disease primers</Title><ISOAbbreviation>Nat Rev Dis Primers</ISOAbbreviation></Journal><ArticleTitle>Merkel cell carcinoma.</ArticleTitle><Pagination><MedlinePgn>17077</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrdp.2017.77</ELocationID><Abstract><AbstractText>Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations. Notably, in the Northern hemisphere, the majority of MCC cases are of viral aetiology; by contrast, in areas with high UV exposure, UV-mediated carcinogenesis is predominant. The two aetiologies share similar clinical, histopathological and prognostic characteristics. MCC presents with a solitary cutaneous or subcutaneous nodule, most frequently in sun-exposed areas. In fact, UV exposure is probably involved in both viral-mediated and non-viral-mediated carcinogenesis, by contributing to immunosuppression or DNA damage, respectively. Confirmation of diagnosis relies on analyses of histological features and immunological marker expression profiles of the lesion. At primary diagnosis, loco-regional metastases are already present in ∼30% of patients. Excision of the tumour is the first-line therapy; if not feasible, radiotherapy can often effectively control the disease. Chemotherapy was the only alternative in advanced-stage or refractory MCC until several clinical trials demonstrated the efficacy of immune-checkpoint inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Jürgen C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Departments of Translational Skin Cancer Research and Dermatology, University Hospital Essen, Universitätsstrasse 1, 45141 Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Clinical Epidemiology; c/o Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Department of Epidemiology, Boston University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCaprio</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Merkel Cell Carcinoma Center of Excellence, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerroni</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebbé</LastName><ForeName>Celeste</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>APHP, Department of Dermatology, Saint-Louis Hospital, Sorbonne Paris Cité Université Paris Diderot, INSERM U976, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veness</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology and Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nghiem</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Dis Primers</MedlineTA><NlmUniqueID>101672103</NlmUniqueID><ISSNLinking>2056-676X</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29072302</ArticleId><ArticleId IdType="pii">nrdp201777</ArticleId><ArticleId IdType="doi">10.1038/nrdp.2017.77</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000352 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000352 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29072302
|texte= Merkel cell carcinoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29072302" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |